Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 381

1.

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Schauwvlieghe AFAD, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, Henriet SSV, Rijnders BJA, Brüggemann RJM.

Mycoses. 2019 Oct 29. doi: 10.1111/myc.13028. [Epub ahead of print]

PMID:
31660650
2.

External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify Candida auris.

Buil JB, van der Lee HAL, Curfs-Breuker I, Verweij PE, Meis JF.

J Fungi (Basel). 2019 Oct 7;5(4). pii: E94. doi: 10.3390/jof5040094.

3.

A Comparison of Isolation Methods for Black Fungi Degrading Aromatic Toxins.

Quan Y, van den Ende BG, Shi D, Prenafeta-Boldú FX, Liu Z, Al-Hatmi AMS, Ahmed SA, Verweij PE, Kang Y, de Hoog S.

Mycopathologia. 2019 Oct;184(5):653-660. doi: 10.1007/s11046-019-00382-3. Epub 2019 Sep 29.

PMID:
31565783
4.

cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.

Talbot JJ, Frisvad JC, Meis JF, Hagen F, Verweij PE, Hibbs DE, Lai F, Groundwater PW, Samson RA, Kidd SE, Barrs VR, Houbraken J.

Antimicrob Agents Chemother. 2019 Oct 22;63(11). pii: e00632-19. doi: 10.1128/AAC.00632-19. Print 2019 Nov.

5.

The fading boundaries between patient and environmental routes of triazole resistance selection in Aspergillus fumigatus.

Buil JB, Hare RK, Zwaan BJ, Arendrup MC, Melchers WJG, Verweij PE.

PLoS Pathog. 2019 Aug 22;15(8):e1007858. doi: 10.1371/journal.ppat.1007858. eCollection 2019 Aug. No abstract available.

6.

Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi.

Hokken MWJ, Zwaan BJ, Melchers WJG, Verweij PE.

Fungal Genet Biol. 2019 Nov;132:103254. doi: 10.1016/j.fgb.2019.103254. Epub 2019 Jul 19. Review.

7.

Diagnostic-driven management of invasive fungal disease in hematology in the era of prophylaxis and resistance emergence: Dutch courage?

de Kort EA, Maertens J, Verweij PE, Rijnders BJA, Blijlevens NMA.

Med Mycol. 2019 Jun 1;57(Supplement_3):S267-S273. doi: 10.1093/mmy/myz026.

PMID:
31292660
8.

Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study.

Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, Blijlevens NMA, Vonk AG, Rijnders B, Verweij PE, Lagrou K, Maertens J.

Med Mycol. 2019 Jul 9. pii: myz079. doi: 10.1093/mmy/myz079. [Epub ahead of print]

PMID:
31290552
9.

ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies.

Koehler P, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bretagne S, Klingspor L, Lagrou K, Meis JF, Rautemaa-Richardson R, Schelenz S, Hamprecht A, Koehler FC, Kurzai O, Salmanton-García J, Vehreschild JJ, Alanio A, Alastruey-Izquierdo A, Arsic Arsenijevic V, Gangneux JP, Gow NAR, Hadina S, Hamal P, Johnson E, Klimko N, Lass-Flörl C, Mares M, Özenci V, Papp T, Roilides E, Sabino R, Segal E, Talento AF, Tortorano AM, Verweij PE, Hoenigl M, Cornely OA; European Confederation of Medical Mycology (ECMM).

Mycoses. 2019 Oct;62(10):920-927. doi: 10.1111/myc.12963. Epub 2019 Aug 1.

PMID:
31271702
10.

Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.

Resendiz-Sharpe A, Mercier T, Lestrade PPA, van der Beek MT, von dem Borne PA, Cornelissen JJ, De Kort E, Rijnders BJA, Schauwvlieghe AFAD, Verweij PE, Maertens J, Lagrou K.

J Antimicrob Chemother. 2019 Sep 1;74(9):2759-2766. doi: 10.1093/jac/dkz258.

PMID:
31236587
11.

Environmental Hotspots for Azole Resistance Selection of Aspergillus fumigatus, the Netherlands.

Schoustra SE, Debets AJM, Rijs AJMM, Zhang J, Snelders E, Leendertse PC, Melchers WJG, Rietveld AG, Zwaan BJ, Verweij PE.

Emerg Infect Dis. 2019 Jul;25(7):1347-1353. doi: 10.3201/eid2507.181625.

12.

Raw genome sequence data for 13 isogenic Aspergillus fumigatus strains isolated over a 2 year period from a patient with chronic granulomatous disease.

Ballard E, Zoll J, Melchers WJG, Brown AJP, Warris A, Verweij PE.

Data Brief. 2019 May 23;25:104021. doi: 10.1016/j.dib.2019.104021. eCollection 2019 Aug.

13.

In Vitro Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Fusarium Isolates Recovered from Fungal Keratitis Patients.

Oliveira Dos Santos C, Kolwijck E, van der Lee HA, Tehupeiory-Kooreman MC, Al-Hatmi AMS, Matayan E, Burton MJ, Eggink CA, Verweij PE.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e02669-18. doi: 10.1128/AAC.02669-18. Print 2019 Aug.

14.

Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in Aspergillus fumigatus azole resistance via a non-cyp51A mediated resistance mechanism.

Ballard E, Weber J, Melchers WJG, Tammireddy S, Whitfield PD, Brakhage AA, Brown AJP, Verweij PE, Warris A.

Fungal Genet Biol. 2019 Sep;130:98-106. doi: 10.1016/j.fgb.2019.05.005. Epub 2019 May 23.

15.

Influenza coinfection: be(a)ware of invasive aspergillosis.

Verweij PE, Brüggemann RJM, Wauters J, Rijnders BJA, Chiller T, van de Veerdonk F.

Clin Infect Dis. 2019 May 11. pii: ciz391. doi: 10.1093/cid/ciz391. [Epub ahead of print] No abstract available.

PMID:
31077266
16.

Aspergillosis related to severe influenza: A worldwide phenomenon?

Liu WL, Yu WL, Chan KS, Yang CC, Wauters J, Verweij PE.

Clin Respir J. 2019 Aug;13(8):540-542. doi: 10.1111/crj.13036. Epub 2019 May 26. No abstract available.

PMID:
31074569
17.

Relevance of heterokaryosis for adaptation and azole-resistance development in Aspergillus fumigatus.

Zhang J, Snelders EE, Zwaan BJ, Schoustra SE, Kuijper EJ, Arendrup MC, Melchers WJG, Verweij PE, Debets AJM.

Proc Biol Sci. 2019 Feb 13;286(1896):20182886. doi: 10.1098/rspb.2018.2886.

PMID:
30963936
18.

Nontuberculous mycobacterial pulmonary disease and Aspergillus co-infection: Bonnie and Clyde?

Geurts K, Zweijpfenning SMH, Pennings LJ, Schildkraut JA, Boeree MJ, Magis-Escurra C, van der Lee H, Verweij PE, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 4;54(1). pii: 1900117. doi: 10.1183/13993003.00117-2019. Print 2019 Jul. No abstract available.

PMID:
30956203
19.

Triazole Antifungal Susceptibility Patterns among Aspergillus Species in Québec, Canada.

Cheng MP, Lawandi A, Lee TC, Dufresne PJ, Seidel D, Verweij PE, Cornely OA, Sheppard DC.

J Clin Microbiol. 2019 May 24;57(6). pii: e00404-19. doi: 10.1128/JCM.00404-19. Print 2019 Jun. No abstract available.

PMID:
30918044
20.

Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands.

Engel TGP, Erren E, Vanden Driessche KSJ, Melchers WJG, Reijers MH, Merkus P, Verweij PE.

Emerg Infect Dis. 2019 Apr;25(4):797-799. doi: 10.3201/eid2504.181110.

21.

Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device.

Mercier T, Schauwvlieghe A, de Kort E, Dunbar A, Reynders M, Guldentops E, Rijnders B, Verweij PE, Lagrou K, Maertens J.

J Clin Microbiol. 2019 Mar 28;57(4). pii: e01913-18. doi: 10.1128/JCM.01913-18. Print 2019 Apr.

22.

Phenotypic plasticity and the evolution of azole resistance in Aspergillus fumigatus; an expression profile of clinical isolates upon exposure to itraconazole.

Hokken MWJ, Zoll J, Coolen JPM, Zwaan BJ, Verweij PE, Melchers WJG.

BMC Genomics. 2019 Jan 9;20(1):28. doi: 10.1186/s12864-018-5255-z.

23.

Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management.

Lestrade PPA, Meis JF, Melchers WJG, Verweij PE.

Clin Microbiol Infect. 2019 Jul;25(7):799-806. doi: 10.1016/j.cmi.2018.11.027. Epub 2018 Dec 21. Review.

PMID:
30580035
24.

Trends in Azole Resistance in Aspergillus fumigatus, the Netherlands, 1994-2016.

Buil JB, Snelders E, Denardi LB, Melchers WJG, Verweij PE.

Emerg Infect Dis. 2019 Jan;25(1):176-178. doi: 10.3201/eid2501.171925.

25.

Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients - A Dutch, multicentre study.

Engel TGP, Slabbers L, de Jong C, Melchers WJG, Hagen F, Verweij PE, Merkus P, Meis JF; Dutch Cystic Fibrosis Fungal Collection Consortium.

J Cyst Fibros. 2019 Mar;18(2):221-226. doi: 10.1016/j.jcf.2018.11.012. Epub 2018 Dec 1.

PMID:
30514613
26.

Genotyping of Aspergillus fumigatus in Formalin-Fixed Paraffin-Embedded Tissues and Serum Samples From Patients With Invasive Aspergillosis.

de Groot T, Hagen F, Vreuls W, Verweij PE, Chowdhary A, Meis JF.

Front Cell Infect Microbiol. 2018 Oct 23;8:377. doi: 10.3389/fcimb.2018.00377. eCollection 2018.

27.

Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study.

Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, Schalekamp S, van der Velden WJFM, Kuiper EJ, van Paassen J, van der Hoven B, van der Lee HA, Melchers WJG, de Haan AF, van der Hoeven HL, Rijnders BJA, van der Beek MT, Verweij PE.

Clin Infect Dis. 2019 Apr 24;68(9):1463-1471. doi: 10.1093/cid/ciy859.

PMID:
30307492
28.

Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment.

Vanderbeke L, Spriet I, Breynaert C, Rijnders BJA, Verweij PE, Wauters J.

Curr Opin Infect Dis. 2018 Dec;31(6):471-480. doi: 10.1097/QCO.0000000000000504. Review.

PMID:
30299367
29.

How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates.

Guinea J, Verweij PE, Meletiadis J, Mouton JW, Barchiesi F, Arendrup MC; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).

Clin Microbiol Infect. 2019 Jun;25(6):681-687. doi: 10.1016/j.cmi.2018.09.008. Epub 2018 Sep 28. Review.

PMID:
30268672
30.

Epidemiology of Aspergillus species causing keratitis in Mexico.

Al-Hatmi AMS, Castro MA, de Hoog GS, Badali H, Alvarado VF, Verweij PE, Meis JF, Zago VV.

Mycoses. 2019 Feb;62(2):144-151. doi: 10.1111/myc.12855. Epub 2018 Oct 14.

PMID:
30256460
31.

In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis.

Omran SM, Taghizadeh-Armaki M, Zarrinfar H, Hedayati MT, Abastabar M, Moqarabzadeh V, Ansari S, Saber S, Hoseinnejad A, Miri A, Verweij PE, Seyedmousavi S.

J Infect Chemother. 2019 Feb;25(2):157-160. doi: 10.1016/j.jiac.2018.07.018. Epub 2018 Sep 18.

PMID:
30241879
32.

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates.

Buil JB, Hagen F, Chowdhary A, Verweij PE, Meis JF.

J Fungi (Basel). 2018 Aug 29;4(3). pii: E103. doi: 10.3390/jof4030103.

33.

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.

Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J; Dutch-Belgian Mycosis study group.

Lancet Respir Med. 2018 Oct;6(10):782-792. doi: 10.1016/S2213-2600(18)30274-1. Epub 2018 Jul 31.

PMID:
30076119
34.

Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950-2017: protocol for a systematic review.

Nyazika TK, Tatuene JK, Kenfak-Foguena A, Verweij PE, Meis JF, Robertson VJ, Hagen F.

BMJ Open. 2018 Jul 30;8(7):e020654. doi: 10.1136/bmjopen-2017-020654.

35.

Discovery and characterization of novel Aspergillus fumigatus mycoviruses.

Zoll J, Verweij PE, Melchers WJG.

PLoS One. 2018 Jul 25;13(7):e0200511. doi: 10.1371/journal.pone.0200511. eCollection 2018.

36.

Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Van Dijck P, Sjollema J, Cammue BP, Lagrou K, Berman J, d'Enfert C, Andes DR, Arendrup MC, Brakhage AA, Calderone R, Cantón E, Coenye T, Cos P, Cowen LE, Edgerton M, Espinel-Ingroff A, Filler SG, Ghannoum M, Gow NAR, Haas H, Jabra-Rizk MA, Johnson EM, Lockhart SR, Lopez-Ribot JL, Maertens J, Munro CA, Nett JE, Nobile CJ, Pfaller MA, Ramage G, Sanglard D, Sanguinetti M, Spriet I, Verweij PE, Warris A, Wauters J, Yeaman MR, Zaat SAJ, Thevissen K.

Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638. Review.

37.

Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.

Arendrup MC, Verweij PE, Mouton JW, Lagrou K, Meletiadis J.

J Antimicrob Chemother. 2018 Aug 1;73(8):2274. doi: 10.1093/jac/dky218. No abstract available.

PMID:
29800383
38.

Gene co-expression analysis identifies gene clusters associated with isotropic and polarized growth in Aspergillus fumigatus conidia.

Baltussen TJH, Coolen JPM, Zoll J, Verweij PE, Melchers WJG.

Fungal Genet Biol. 2018 Jul;116:62-72. doi: 10.1016/j.fgb.2018.04.013. Epub 2018 Apr 26.

39.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduijn JK, Rijnders BJA.

Mycoses. 2018 Sep;61(9):656-664. doi: 10.1111/myc.12788. Epub 2018 Jul 13.

PMID:
29687483
40.

Molecular Detection of Azole-Resistant Aspergillus fumigatus in Clinical Samples.

Buil JB, Zoll J, Verweij PE, Melchers WJG.

Front Microbiol. 2018 Mar 21;9:515. doi: 10.3389/fmicb.2018.00515. eCollection 2018. Review.

41.

Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Deng S, Lei W, de Hoog GS, Yang L, Vitale RG, Rafati H, Seyedmousavi M, Tolooe A, van der Lee H, Liao W, Verweij PE, Seyedmousavi S.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00270-18. doi: 10.1128/AAC.00270-18. Print 2018 Jun.

42.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

43.

Triazole resistance surveillance in Aspergillus fumigatus.

Resendiz Sharpe A, Lagrou K, Meis JF, Chowdhary A, Lockhart SR, Verweij PE; ISHAM/ECMM Aspergillus Resistance Surveillance working group.

Med Mycol. 2018 Apr 1;56(suppl_1):83-92. doi: 10.1093/mmy/myx144. Review.

PMID:
29538741
44.

Fusarium metavorans sp. nov.: The frequent opportunist 'FSSC6'.

Al-Hatmi AMS, Ahmed SA, van Diepeningen AD, Drogari-Apiranthitou M, Verweij PE, Meis JF, de Hoog GS.

Med Mycol. 2018 Apr 1;56(suppl_1):144-152. doi: 10.1093/mmy/myx107.

PMID:
29538734
45.

Elevated MIC Values of Imidazole Drugs against Aspergillus fumigatus Isolates with TR34/L98H/S297T/F495I Mutation.

Chen Y, Li Z, Han X, Tian S, Zhao J, Chen F, Su X, Zhao J, Zou Z, Gong Y, Qu F, Qiu G, Wang S, Jia X, Lu Z, Hu M, Huang L, Verweij PE, Han L.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01549-17. doi: 10.1128/AAC.01549-17. Print 2018 May.

46.

In-host microevolution of Aspergillus fumigatus: A phenotypic and genotypic analysis.

Ballard E, Melchers WJG, Zoll J, Brown AJP, Verweij PE, Warris A.

Fungal Genet Biol. 2018 Apr;113:1-13. doi: 10.1016/j.fgb.2018.02.003. Epub 2018 Feb 23.

47.

Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study.

Lestrade PP, van der Velden WJFM, Bouwman F, Stoop FJ, Blijlevens NMA, Melchers WJG, Verweij PE, Donnelly JP.

J Antimicrob Chemother. 2018 May 1;73(5):1389-1394. doi: 10.1093/jac/dkx527.

PMID:
29394399
48.

Antifungal Susceptibility Testing of Fusarium: A Practical Approach.

Al-Hatmi AMS, Curfs-Breuker I, de Hoog GS, Meis JF, Verweij PE.

J Fungi (Basel). 2017 Apr 26;3(2). pii: E19. doi: 10.3390/jof3020019. Review.

49.

Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China.

Deng S, Zhang L, Ji Y, Verweij PE, Tsui KM, Hagen F, Houbraken J, Meis JF, Abliz P, Wang X, Zhao J, Liao W.

Emerg Microbes Infect. 2017 Dec 6;6(12):e109. doi: 10.1038/emi.2017.97.

50.

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Buil JB, Brüggemann RJM, Wasmann RE, Zoll J, Meis JF, Melchers WJG, Mouton JW, Verweij PE.

J Antimicrob Chemother. 2018 Jan 1;73(1):263. doi: 10.1093/jac/dkx425. No abstract available.

PMID:
29112717

Supplemental Content

Loading ...
Support Center